Noxopharm Ltd. · ASX:NOX
Noxopharm — JP Morgan Healthcare Conference 2020
15 slides from Noxopharm's conference presentation, Jan 15, 2020
Slide 1: Noxopharm Corporate Presentation ASX announcement
Date: 15th January 2020 Sydney, Australia For personal use only ASX Limited 20 Bridge Street SYDNEY NSW 2000 Noxopharm Corporate Presentation Sydney, 15th January 2020: Noxopharm (ASX: NOX) is pleased to provide shareholders and the market the attached Noxopharm corporate presentation “Corporate & C
Slide 2: Forward Looking Statements
Forward Looking Statements This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, For personal use only “plan”, “predict”, “pr
Slide 3: Veyonda Corporate & Clinical Overview
January 2020 For personal use only Noxopharm Limited Veyonda® Corporate & Clinical Overview 15th January 2020 DISCOVER DEVELOP DELIVER ASX: NOX © 2020 Noxopharm Ltd. All rights reserved.
Slide 4: Disclaimer
Disclaimer This presentation has been prepared by Noxopharm Limited (NOX or the Company). It should not be considered as an offer or invitation to subscribe for, or purchase any shares in NOX, or as an inducement to purchase any shares in NOX. No agreement to subscribe for securities in NOX will be
Slide 5: Table of Contents
TABLE OF CONTENTS For personal use only Executive Summary Company Details Veyonda® Veyonda® DARRT Noxopharm is seeking to bring LuPIN Veyonda® to market as a first-in- class drug that boosts the efficacy Clinical Program Timing*indicative of radiotherapy in prostate cancer Market Opportunity Nyrada
Slide 6: Executive Summary
Executive Summary ➢ Australian biotech company listed on Australian Securities Exchange (ASX:NOX) For personal use only ➢ Oncology focus ➢ Proprietary drug Veyonda® ➢ First-in-class inhibitor of sphingosine-1-phosphate ➢ Intended as adjunct to radiotherapy ➢ 2 active clinical trials studying improve
Slide 7: Company Details
Company Details For personal use only Noxopharm Limited (Dec 2019) Board and Key Management Listed on Australian Securities Exchange (ASX:NOX) Aug 2016 Dr Graham Kelly. PhD Chairman & CEO Shares on issue 130m Ian Dixon. PhD, MBA Non-Executive Director Share Price A$0.40 Peter Marks. MBA, BEc, LLB No
Slide 8: Veyonda
Veyonda® How Veyonda® works Veyonda ® For personal use only ▪ The active ingredient in Veyonda® is the experimental anti-cancer drug, ▪ Veyonda® (previously known as NOX66) is the Company's proprietary idronoxil oncology drug currently in Phase 1b and Phase 2a clinical trials ▪ The molecular target
Slide 9: DARRT - a novel radiation therapy enhancer
DARRT - a novel radiation therapy enhancer Direct and Abscopal Response to Radiotherapy The key to the success of the DARRT treatment is a combination of two actions: For personal use only ▪ First: expose a small number (1 or 2) of individual tumours to low-dose (20 Gy) radiation. Low-dose is critic
Slide 10: DARRT-2
DARRT-2 DARRT-2 Trial Design Anticipated endpoints For personal use only ▪ Phase 2 clinical trial protocol development under way ▪ Key primary endpoint: Overall survival at 12-months ▪ Men with mCRPC post-taxane and post-enzalutamide/abiraterone ▪ Secondary endpoints: ▪ In combination with best supp
Slide 11: LuPIN
LuPIN Aim of the LuPIN study What is 177Lu-PSMA-617 For personal use only A major aim of the LuPIN trial is to see if Veyonda® can boost the 177Lu-PSMA-617 is an experimental radioactive drug that was the subject of effectiveness of 177Lu-PSMA-617 radiation therapy so that more men are a US$6 billio
Slide 12: Indicative Clinical Program Timing
Indicative Clinical Program Timing For personal use only MarQ2020 MarQ2021 DecQ2019 DecQ2020 DecQ2021 SepQ2020 SepQ2021 JunQ2020 JunQ2021 DARRT -1 complete, Indicative Clinical Program Timing final statistical results due March 2020 DARRT-1 Phase 1 clinical trial complete Dec Q 2019 Phase 1 statisti
Slide 13: Market Opportunity
2 Market Opportunity Market Opportunity For personal use only Noxopharm believes ▪ Noxopharm believes Veyonda® has potential applications in most forms of solid cancer as both a radio-enhancer Veyonda® has potential and chemo-enhancer use in most forms of solid ▪ Noxopharm has selected radio-enhance
Slide 14: Nyrada Inc.
2 Nyrada Inc. For personal use only NYRADA ▪ Nyrada is a pre-clinical stage, drug company specialising in the development of novel small molecule drugs Nyrada is a U.S.-registered pertaining to the underlying pathological processes involved in cardiovascular, neurodegenerative and spin-off subsidiar
Slide 15: Investment Highlights
Investment Highlights Noxopharm Investment Highlights For personal use only ▪ Significant clinical milestones over next 12 months from DARRT and LuPIN trials ▪ Potential standard of care: Noxopharm believes that its DARRT and LuPIN treatments have the potential to become standard of care for late-st